Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Omega 3 Prescription Drugs Companies

Omega-3 prescription drugs companies play a pivotal role in harnessing the health benefits of essential fatty acids for various medical conditions. These companies specialize in the development and production of pharmaceutical-grade omega-3 formulations, catering to the growing demand for therapeutic interventions. Leveraging advanced research and technology, these companies focus on creating prescription medications that contain concentrated and purified omega-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Omega 3 Prescription Drugs Key Companies

Latest Omega 3 Prescription Drugs Companies Update:

October 2023:

Amarin Corporation's Vascepa (icosapent ethyl) received an expanded label from the FDA for the treatment of severe hypertriglyceridemia, including patients with mixed dyslipidemia (elevated LDL-C and triglycerides). This expanded indication could increase potential patient population for Vascepa.

December 2023:

EPA Therapeutics announced topline results from a Phase 3 trial (REDUCE-IT) showing that its prescription omega-3 drug, Epanova, did not meet the primary endpoint of reducing major adverse cardiovascular events (MACE) in a high-risk cardiovascular population already on statin therapy. However, the study did show some positive secondary outcomes, and further analysis is ongoing.

September 2023:

Amarin Corporation presented positive data from a Phase 4 study demonstrating the long-term safety and efficacy of Vascepa in reducing triglyceride levels and cardiovascular risk factors.

List of Omega 3 Prescription Drugs Key companies in the market

Abbott

Amarin Pharmaceuticals Ireland Ltd.

GSK plc

Natrapharm, Inc. (Patriot Pharmaceutical Corp.)

Viatris Inc.

Grupo Ferrer Internacional, S.A.

Camber Pharmaceuticals, Inc.

Dr. Reddy’s Laboratories Ltd.

Zydus Group

Hikma Pharmaceuticals PLC

Omega 3 Prescription Drugs Market Highlights:

Omega 3 Prescription Drugs Market Size

Omega 3 Prescription Drugs Market Trends

Omega 3 Prescription Drugs Market Analysis

Omega 3 Prescription Drugs Market Share

Omega 3 Prescription Drugs Market Highlights:

Omega 3 Prescription Drugs Market Trends

Omega 3 Prescription Drugs Market Analysis

Omega 3 Prescription Drugs Market Share

Omega 3 Prescription Drugs Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.